Skip to content
Review

Phosphatidylethanolamine-mediated metabolic membrane remodeling in obesity-associated Alzheimer’s disease: mechanisms, neuroimmune crosstalk, and therapeutic potential

Sep 2026 · Metabolic brain disease · Vol 41 · 0 citations · 60 references
Medicine

TL;DR

This review critically examines the molecular and cellular mechanisms underlying PE-mediated adipose–brain crosstalk in obesity-associated Alzheimer’s disease, with emphasis on mitochondrial dysfunction, blood–brain barrier disruption, ferroptosis, membrane remodeling, and microglial activation.

View source

Similar papers

Review 2026

Brain lipid dysregulation as a driver of energy metabolism failure in Alzheimer's disease.

This chapter addresses the gap and consolidates existing information connecting lipid modifications to metabolic dysfunction in AD, emphasizing molecular pathways and prospective treatment strategies aimed at lipid metabolism to re-establish bioenergetic equilibrium.

Nitin Yadav, Jyotirmoy Banerjee, Manisha Tiwari et al. · 0 citations
Review 2026

Metabolic therapeutic targets in Alzheimer's disease.

This chapter examines key metabolic pathways implicated in AD, including cerebral glucose hypometabolism, brain insulin resistance, impaired glycolysis, mitochondrial oxidative phosphorylation deficits, oxidative stress, and altered mitochondrial dynamics, and discusses therapeutic strategies aimed at restoring metabol...

Ignatius Raymond Peter L, Debojyoti Chatterjee, A. F. Chrishone et al. · 0 citations
Review 2026

Metabolic dysregulation in Alzheimer's disease: Mechanisms, markers, and therapeutic prospects.

The chapter outlines the current evidences on dysregulated metabolic processes, and highlights emerging metabolic biomarkers that are identified through advanced neuroimaging modalities, plasma/cerebrospinal fluid (CSF) profiles, lipidomic signatures and markers of mitochondrial impairment, underscoring their diagnosti...

Radhika Mittal, Priya, Jyotirmoy Banerjee et al. · 0 citations
Review Aug 2026

Neuroinflammatory and molecular pathways in Alzheimer’s disease: mechanistic crosstalk and emerging therapeutic opportunities

Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.

Abhay Thakur, Rohit Sharma, Sneha Kumari et al. · 0 citations
Review Open access Sep 2026

Targeting lipid homeostasis for preventive intervention in brain aging and Alzheimer’s disease

Lipids are essential for brain structure and function, contributing to membrane integrity, synaptic activity, signal transduction, and energy metabolism. Converging evidence from human genetics, epidemiology, lipidomics, and neuroimaging indicates that disrupted lipid homeostasis is an early and biologically rele...

L. Berliocchi, M. Grimm, Tobias Hartmann et al. · 0 citations
Review Open access Sep 2026

Synaptic mitochondrial dysfunction and Alzheimer’s disease: from molecular mechanisms to therapeutic strategies

A organelle-centered perspective will clarify AD pathogenesis and help guide the development of next-generation neuroprotective therapies, and highlight the essential requirements for building one, centered on synaptic mitochondrial bioenergetics and quality control.

Yu-Xin Wang, Wei-Dong Wu, Li-Shuang Yan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.